**Materials Design Analysis Reporting (MDAR)**

**Checklist for Authors**

The [MDAR framework](https://osf.io/xfpn4/) establishes a minimum set of requirements in transparent reporting mainly applicable to studies in the life sciences.

*eLife* asks authors to **provide detailed information within their article** to facilitate the interpretation and replication of their work. Authors can also upload supporting materials to comply with relevant reporting guidelines for health-related research (see [EQUATOR Network](http://www.equator-network.org/%20)), life science research (see the [BioSharing Information Resource](http://biosharing.org/)), or animal research (see the [ARRIVE Guidelines](http://www.plosbiology.org/article/info%3Adoi/10.1371/journal.pbio.1000412) and the [STRANGE Framework](https://doi.org/10.1038/d41586-020-01751-5); for details, see *eLife*’s [Journal Policies](https://reviewer.elifesciences.org/author-guide/journal-policies)). Where applicable, authors should refer to any relevant reporting standards materials in this form.

For all that apply, please note **where in the article** the information is provided. Please note that we also collect information about data availability and ethics in the submission form.

**Materials:**

|  |  |  |
| --- | --- | --- |
| **Newly created materials** | **Indicate where provided: section/figure legend** | **N/A** |
| The manuscript includes a dedicated "materials availability statement" providing transparent disclosure about availability of newly created materials including details on how materials can be accessed and describing any restrictions on access. |  | ✓ |
|  |  |  |
| **Antibodies** | **Indicate where provided: section/figure legend** | **N/A** |
| For commercial reagents, provide supplier name, catalogue number and [RRID](https://scicrunch.org/resources), if available. |  | ✓ |
|  |  |  |
| **DNA and RNA sequences** | **Indicate where provided: section/figure legend** | **N/A** |
| Short novel DNA or RNA including primers, probes: Sequences should be included or deposited in a public repository. |  | ✓ |
|  |  |  |
| **Cell materials** | **Indicate where provided: section/figure legend** | **N/A** |
| Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID. |  | ✓ |
| Primary cultures: Provide species, strain, sex of origin, genetic modification status.  |  | ✓ |
|  |  |  |
| **Experimental animals** | **Indicate where provided: section/figure legend** | **N/A** |
| Laboratory animals or Model organisms: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID. |  | ✓ |
| Animal observed in or captured from the field: Provide species, sex, and age where possible. |  | ✓ |
|  |  |  |
| **Plants and microbes** | **Indicate where provided: section/figure legend** | **N/A** |
| Plants: provide species and strain, ecotype and cultivar where relevant, unique accession number if available, and source (including location for collected wild specimens). |  | ✓ |
| Microbes: provide species and strain, unique accession number if available, and source. |  | ✓ |
|  |  |  |
| **Human research participants** | **Indicate where provided: section/figure legend) or state if these demographics were not collected** | **N/A** |
| If collected and within the bounds of privacy constraints report on age, sex, gender and ethnicity for all study participants. | Age and gender information of human research participants was collected in this study. The demographics information can be found in the *MATERIALS AND METHOD*: *Infant subjects* section.  |  |

**Design:**

|  |  |  |
| --- | --- | --- |
| **Study protocol** | **Indicate where provided: section/figure legend** | **N/A** |
| If the study protocol has been pre-registered, provide DOI. For clinical trials, provide the trial registration number OR cite DOI. |  | ✓ |
|  |  |  |
| **Laboratory protocol** | **Indicate where provided: section/figure legend** | **N/A** |
| Provide DOI OR other citation details if detailed step-by-step protocols are available. | The data acquisition information can be found in the *MATERIALS AND METHOD: Data acquisition* section. Legend of Figure 2a also demonstrates the acquisition protocol. |  |
|  |  |  |
| **Experimental study design (statistics details) \*** |
| **For in vivo studies: State whether and how the following have been done** | **Indicate where provided: section/figure legend. If it could have been done, but was not, write “not done”** | **N/A** |
| Sample size determination | Sample size was justified. Significant heterogeneity of regional cerebral blood flow (rCBF) across brain regions in Figure 2-figure supplement 2 and significant age-dependent rCBF changes in Figure 3 indicate that the current sample size had sufficient power to capture the inhomogeneity of rCBF measurements and rCBF increase rates across brain regions. For both statistical analyses, false discovery rate corrections were conducted. Of the note, infant MRI, especially multi-modality data including pCASL, phase-contrast MRI, rs-fMRI and structural MRI, was extremely difficult to acquire. After quality control, all evaluable datasets from forty-eight subjects were included in data analysis. |  |
| Randomisation | Randomisation was conducted by nonparametric permutation tests and randomly selecting voxels for rCBF and functional connectivity (FC) measurements, with details in *MATERIALS AND METHODS:* *Coupling between rCBF and FC during the infant brain development* section. Legends of Figure 4, Figure 5 and Figure 5-figure supplement 1-2 also provide information of randomisation. |  |
| Blinding |  | ✓ |
| Inclusion/exclusion criteria | Inclusion/exclusion criteria for infant participants can be found in the *MATERIALS AND METHODS*: *Infant subjects* section. |  |
|  |  |  |
| **Sample definition and in-laboratory replication** | **Indicate where provided: section/figure legend** | **N/A** |
| State number of times the experiment was replicated in the laboratory. | The details about replication can be found in the *MATERIALS AND METHODs*: *Measurement of rCBF with pCASL perfusion MRI and calibrated by PC MRI* section and Figure 2 – figure supplement 1. Additional information for replication can be found in criteria for exclusion/inclusion of infant participants in the *MATERIALS AND METHODS:* *Infant Subjects* section.  |  |
| Define whether data describe technical or biological replicates. | Information about data replicates can be found in the *MATERIALS AND METHOD*: *Measurement of rCBF with pCASL perfusion MRI and calibrated by PC MRI* section. In addition, quality control of MRI data by visual inspection of experienced pediatric radiologists for replication was also included in the *MATERIALS AND METHODS:* *Data acquisition.*  |  |
|  |  |  |
| **Ethics** | **Indicate where provided: section/submission form** | **N/A** |
| Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | This information can be found in the *MATERIALS AND METHODS: Infant subjects* section and the Ethics statement in the submission form. Specifically, informed parental consents were obtained from the subject’s parent. The Institutional Review Board of both Beijing Children’s Hospital Research Ethics Committee (Approval number 2016-36) approved study procedures. |  |
| Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. |  | ✓ |
| Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why. |  | ✓ |
|  |  |  |
| **Dual Use Research of Concern (DURC)** | **Indicate where provided: section/submission form** | **N/A** |
| If study is subject to dual use research of concern regulations, state the authority granting approval and reference number for the regulatory approval. |  | ✓ |

**Analysis:**

|  |  |  |
| --- | --- | --- |
| **Attrition** | **Indicate where provided: section/figure legend** | **N/A** |
| Describe whether exclusion criteria were pre-established. Report if sample or data points were omitted from analysis. If yes, report if this was due to attrition or intentional exclusion and provide justification. | Exclusion criteria were only applied to the data acquisition. No exclusion criteria were pre-established for data analysis, and no data points were omitted from analysis. Such information was provided in the *MATERIALS AND METHOD*: *Data acquisition* section.  |  |
|  |  |  |
| **Statistics** | **Indicate where provided: section/figure legend** | **N/A** |
| Describe statistical tests used and justify choice of tests. | Statistical analysis methods are described throughout the *RESULTS* and more details can be found in the following *MATERIALS AND METHOD sections,* 1) *Characterization of age-dependent changes of rCBF and FC s*ection for describing F-test for model comparisons (exponential, biphasic and linear models) of age-dependent trendlines; 2) *Test of heterogeneity of rCBF across functional network ROIs s*ection for describingone-way analysis of variance (ANOVA) test and paired t-tests for examine the difference of rCBF values among different ROIs. Significant interaction between regions and age was tested with an analysis of covariance (ANCOVA) test where age was used a covariate; 3) *Coupling between rCBF and FC during the infant brain development* sectionfor describing Deming regression and nonparametric permutation test for coupling between rCBF and FC. Statistical test methods and results were also described in the legends of Figure 1-figure supplement 2, Figure 2-figure supplement 1, Figure 2-figure supplement 2, Figure 3, Figure 4, Figure 5, and Figure 5-figure supplement 1-2.  |  |
|  |  |  |
| **Data availability** | **Indicate where provided: section/submission form** | **N/A** |
| For newly created and reused datasets, the manuscript includes a data availability statement that provides details for access (or notes restrictions on access). | This information can be found in the *Data Availability* section in the submission form. |  |
| When newly created datasets are publicly available, provide accession number in repository OR DOI and licensing details where available. | This information can be found in the *Data Availability* section in the submission form. The newly created datasets are publicly available, but we will not acquire a DOI or a license for the data. |  |
| If reused data is publicly available provide accession number in repository OR DOI, OR URL, OR citation. |  | ✓ |
|  |  |  |
| **Code availability** | **Indicate where provided: section/figure legend** | **N/A** |
| For any computer code/software/mathematical algorithms essential for replicating the main findings of the study, whether newly generated or re-used, the manuscript includes a data availability statement that provides details for access or notes restrictions. | This information can be found in the *Data Availability* section in the submission form. |  |
| Where newly generated code is publicly available, provide accession number in repository, OR DOI OR URL and licensing details where available. State any restrictions on code availability or accessibility. | This information can be found in the *Data Availability* section in the submission form. The newly generated code is publicly available, but we will not acquire a DOI or a license for the code. |  |
| If reused code is publicly available provide accession number in repository OR DOI OR URL, OR citation. |  | ✓ |

**Reporting:**

The MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives.

|  |  |  |
| --- | --- | --- |
| **Adherence to community standards** | **Indicate where provided: section/figure legend** | **N/A** |
| State if relevant guidelines (e.g., ICMJE, MIBBI, ARRIVE, STRANGE) have been followed, and whether a checklist (e.g., CONSORT, PRISMA, ARRIVE) is provided with the manuscript. |  | ✓ |

\* We provide the following guidance regarding transparent reporting and statistics; we also refer authors to [Ten common statistical mistakes to watch out for when writing or reviewing a manuscript](https://doi.org/10.7554/eLife.48175).

**Sample-size estimation**

* You should state whether an appropriate sample size was computed when the study was being designed
* You should state the statistical method of sample size computation and any required assumptions
* If no explicit power analysis was used, you should describe how you decided what sample (replicate) size (number) to use

**Replicates**

* You should report how often each experiment was performed
* You should include a definition of biological versus technical replication
* The data obtained should be provided and sufficient information should be provided to indicate the number of independent biological and/or technical replicates
* If you encountered any outliers, you should describe how these were handled
* Criteria for exclusion/inclusion of data should be clearly stated
* High-throughput sequence data should be uploaded before submission, with a private link for reviewers provided (these are available from both GEO and ArrayExpress)

**Statistical reporting**

* Statistical analysis methods should be described and justified
* Raw data should be presented in figures whenever informative to do so (typically when N per group is less than 10)
* For each experiment, you should identify the statistical tests used, exact values of N, definitions of center, methods of multiple test correction, and dispersion and precision measures (e.g., mean, median, SD, SEM, confidence intervals; and, for the major substantive results, a measure of effect size (e.g., Pearson's r, Cohen's d)
* Report exact p-values wherever possible alongside the summary statistics and 95% confidence intervals. These should be reported for all key questions and not only when the p-value is less than 0.05.

**Group allocation**

* Indicate how samples were allocated into experimental groups (in the case of clinical studies, please specify allocation to treatment method); if randomization was used, please also state if restricted randomization was applied
* Indicate if masking was used during group allocation, data collection and/or data analysis